| First Author | Pruss KM | Year | 2021 |
| Journal | Nature | Volume | 593 |
| Issue | 7858 | Pages | 261-265 |
| PubMed ID | 33911281 | Mgi Jnum | J:326193 |
| Mgi Id | MGI:7287633 | Doi | 10.1038/s41586-021-03502-6 |
| Citation | Pruss KM, et al. (2021) C. difficile exploits a host metabolite produced during toxin-mediated disease. Nature 593(7858):261-265 |
| abstractText | Several enteric pathogens can gain specific metabolic advantages over other members of the microbiota by inducing host pathology and inflammation. The pathogen Clostridium difficile is responsible for a toxin-mediated colitis that causes 450,000 infections and 15,000 deaths in the United States each year(1); however, the molecular mechanisms by which C. difficile benefits from this pathology remain unclear. To understand how the metabolism of C. difficile adapts to the inflammatory conditions that its toxins induce, here we use RNA sequencing to define, in a mouse model, the metabolic states of wild-type C. difficile and of an isogenic mutant that lacks toxins. By combining bacterial and mouse genetics, we demonstrate that C. difficile uses sorbitol derived from both diet and host. Host-derived sorbitol is produced by the enzyme aldose reductase, which is expressed by diverse immune cells and is upregulated during inflammation-including during toxin-mediated disease induced by C. difficile. This work highlights a mechanism by which C. difficile can use a host-derived nutrient that is generated during toxin-induced disease by an enzyme that has not previously been associated with infection. |
